Rhythm Biosciences Limited
Daniel Payne is a System Engineer at Rhythm Biosciences Limited since April 2024. Previously, Daniel worked at Seer from May 2021 to February 2024, initially as a Software Quality Engineer, where involvement included regulatory compliance and software process validation. Daniel also served as a Machine Learning Engineer at Seer, leading efforts that culminated in the release of the world’s first seizure forecasting app in 2022, and worked as a Data Scientist at the University of Melbourne from July 2016 to May 2021, focusing on machine learning applications for seizure forecasting via iEEG recordings. Earlier experience includes roles as a Research Engineer at Seer, a Research Intern at IBM developing machine learning models for seizure detection, and a Summer Intern at the Bionics Institute. Daniel's educational background comprises a Doctor of Philosophy in Biomedical/Medical Engineering and a Doctor of Medicine from the University of Melbourne, along with a Bachelor's Degree in Biomedical Sciences.
This person is not in the org chart
This person is not in any teams
Rhythm Biosciences Limited
Rhythm Biosciences is an innovative Australian, publicly listed medical diagnostics company, with a focus on delivering simple, affordable blood tests for the accurate detection of cancers, providing physicians with accurate and reliable diagnostic tools. Early detection is critical to improving patient outcomes and reducing the global burden of cancer. ColoSTAT®, Rhythm Bioscience’s first simple blood-based cancer test, designed for the early detection of colorectal cancer, has been developed initially as an alternative screening test for individuals unable to or are unwilling to use currently available screening modalities. Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.